论文部分内容阅读
[目的]探讨适量补钠对慢性重型病毒性肝炎低钠血症疗效的影响。[方法]将120例确诊的慢性重型病毒性肝炎中、重度低钠血症患者,随机分为限钠组60例,不限钠组60例,在常规治疗的基础上,分别采用适量补钠与限钠治疗,观察2组腹水消退时间,腹水消退率,病死率,并发症发生率。[结果]不限钠组腹水好转36例(60.0%),腹水消退时间20~85 d,平均48.5 d;死亡24例;发生肝肾综合征25例(41.67%);肝性脑病39例(65.00%)。限钠组腹水好转25例(41.67%),腹水消退时间25~90 d,平均58.5 d;死亡35例(58.33%);发生肝肾综合征40例(66.67%);肝性脑病52例(86.67%)。不限钠组腹水消退率及消退时间、肝肾综合征及肝性脑病发生率和病死率均明显低于限钠组(均P<0.05)。[结论]对慢性重型病毒性肝炎低钠血症患者,及时适量补充钠盐治疗,是一种切实有效的重要辅助治疗方法。
[Objective] To investigate the effect of sodium supplementation on curative effect of hyponatremia in patients with chronic severe viral hepatitis. [Methods] 120 patients with confirmed chronic severe hepatitis and moderate to severe hyponatremia were randomly divided into sodium limitation group (n = 60) and sodium group (n = 60). On the basis of routine treatment, And limited sodium treatment, observation group 2 ascites regression time, ascites regression rate, mortality, complication rate. [Results] Ascites was improved in 36 cases (60.0%) in ascending sodium group and 20 ~ 85 days in ascites group (average 48.5 days). 24 cases died of hepatorenal syndrome (41.67%), 39 cases of hepatic encephalopathy 65.00%). 25 cases (41.67%) had ascites improvement in the limited sodium group, 25 ~ 90 days (58.53%) died of ascites, 35 (58.33%) died of hepatocirrhosis, 52 cases (66.67% 86.67%). Not limited sodium group ascites regression rate and regression time, hepatorenal syndrome and hepatic encephalopathy incidence and mortality were significantly lower than the sodium limit group (all P <0.05). [Conclusion] It is an effective and effective adjuvant therapy for patients with chronic severe viral hepatitis and hyponatremia who receive adequate and timely sodium supplementation.